Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | CETP | P11597 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | IL1RN | P18510 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325439 | 0.79 | CYP2D6 (0.58) | CYP2D6TSHRCETPALDH1A1POLB | |
| SCHEMBL1101314 | 0.77 | TSHR (0.67) | CYP2D6TSHRCETPALDH1A1POLB | |
| SCHEMBL28543472 | 0.75 | TSHR (0.64) | CYP2D6TSHRCETPALDH1A1POLB | |
| SCHEMBL8949611 | 0.75 | CYP2D6 (0.67) | CYP2D6TSHRCETPALDH1A1POLB | |
| SCHEMBL2488080 | 0.74 | TSHR (0.69) | CYP2D6TSHRCETPALDH1A1POLB | |
| SCHEMBL5053183 | 0.74 | CYP2D6 (0.56) | CYP2D6TSHRCETPALDH1A1POLB | |
| SCHEMBL2486994 | 0.74 | TSHR (0.62) | CYP2D6TSHRCETPALDH1A1POLB | |
| SCHEMBL28103039 | 0.74 | TSHR (0.62) | CYP2D6TSHRCETPALDH1A1POLB | |
| SCHEMBL6030731 | 0.73 | TSHR (0.88) | CYP2D6TSHRCETPPOLBERAP1 | |
| SCHEMBL20575202 | 0.73 | TSHR (0.67) | CYP2D6TSHRCETPALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379571-A1 | METHOD FOR THE PRODUCTION OF MIXED-SUBSTITUTED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | Clariant International Ltd. (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20110245386-A1 | Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-06 | — | — | US | disclosed |
| WO-2010069419-A1 | METHOD FOR THE PRODUCTION OF MIXED-SUBSTITUTED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245386-A1 | Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof | HAO2, ACSL3, SCO2 | CYP2D6 1340/4885TSHR 852/4885CETP 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.